AC
TVTX icon

Armistice Capital’s Travere Therapeutics TVTX Stock Holding History

Armistice Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
+500,000
New +$22.2M 0.35% 45

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital's TVTX Position: Q2 2026 in Review

Armistice Capital reduced its Travere Therapeutics (TVTX) stake by 68% in Q2 2026, selling an estimated $147M and leaving 1,572,539 shares worth $89.3M. The position accounts for 1.09% of the portfolio, ranked #10.

Armistice Capital first reported a position in TVTX in Q4 2014 and has held it in 23 quarters since. The position peaked at $161M in Q1 2023. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Armistice Capital held 1,572,539 shares of Travere Therapeutics worth $89.3M as of Q2 2026.
  • Armistice Capital sold 3,324,878 Travere Therapeutics shares in Q2 2026, an estimated $147M.
  • Travere Therapeutics made up 1.09% of Armistice Capital's portfolio in Q2 2026, its #10 holding.
  • Armistice Capital first reported a position in Travere Therapeutics in Q4 2014 and has held it in 23 quarters since.
  • Armistice Capital's Travere Therapeutics position peaked at $161M in Q1 2023.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.